Form 4: Vor Biopharma CEO Robert Ang Reports Changes in Beneficial Ownership
SEC Form 4 Filing
Robert Ang, CEO of Vor Biopharma, reports the disposal of common stock to cover tax obligations related to the settlement of restricted stock units.
Summary
- On May 1, 2025, Robert Ang, the President and CEO of Vor Biopharma Inc., disposed of 2,751 shares of common stock at a price of $0.66 per share to cover tax withholding obligations.
- Following this transaction, Ang directly owns 916,201 shares of Vor Biopharma common stock.
- An additional 2,522 shares were disposed of on the same day for the same reason, resulting in a final holding of 913,679 shares.
Sentiment
Score: 5
Explanation: Neutral sentiment as the filing reports a routine transaction related to tax obligations.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates the CEO's stock disposal to cover tax obligations, which is a common practice.
Stakeholder Impact
- The transaction has a minimal impact on shareholders as it is a routine disposal of shares for tax purposes.
Key Dates
| Date | Description |
|---|---|
| 05/01/2025 | Date of stock disposal for tax withholding obligations. |
| 05/02/2025 | Date of signature by Attorney-in-Fact. |
Keywords
Form 4, Beneficial Ownership, Robert Ang, Vor Biopharma, Stock Disposal, Tax Withholding, CEO
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.